Allos Therapeutics to Report Second Quarter 2008 Results on August 5, 2008
22 7월 2008 - 9:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it
will report second quarter 2008 results on Tuesday, August 5, 2008,
after the U.S. financial markets close. Paul L. Berns, President
and Chief Executive Officer, and other members of Allos' senior
management will provide a company update and discuss results via
webcast and conference call on Tuesday, August 5, 2008 at 4:15 p.m.
ET. The webcast of this call will be available from the homepage
and the investors/media section of the Company's website,
www.allos.com, and will be archived for 30 days. Alternatively,
callers may participate in the conference call by dialing
800-762-8779 (domestic) or 480-248-5081 (international). Webcast
and telephone replays of the conference call will be available
approximately two hours after the completion of the call through
Friday, August 15, 2008. Callers can access the replay by dialing
800-406-7325 (domestic) or 303-590-3030 (international). The
passcode is 3900919#. About Allos Therapeutics Allos Therapeutics
is a biopharmaceutical company focused on developing and
commercializing small molecule therapeutics for the treatment of
cancer.�The Company's lead product candidate, PDX (pralatrexate),
is a novel antifolate currently under evaluation in a pivotal Phase
2 (PROPEL) trial in patients with relapsed or refractory peripheral
T-cell lymphoma. The PROPEL trial is being conducted under an
agreement reached with the U.S. Food and Drug Administration under
its special protocol assessment, or SPA, process. The Company is
also investigating PDX in patients with bladder cancer, non-small
cell lung cancer and a range of lymphoma sub-types.�The Company's
other product candidate�is RH1, a targeted chemotherapeutic agent
currently being evaluated in a Phase 1 trial in patients with
advanced solid tumors or non-Hodgkin�s Lymphoma (NHL). The Company
currently retains exclusive worldwide rights to PDX and RH1 for all
indications. For additional information, please visit the Company�s
website at www.allos.com. Safe Harbor Statement The 2008 second
quarter results press release and conference call will contain
forward-looking statements that involve significant risks and
uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2007 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the
conference call. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics, Inc. News Articles